TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3177858

Group type: EXPERIMENTAL
Intervention: Incentive spirometer as part of postoperative chest physiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine postoperative physiotherapy as dictated by needs
Number of subjects: 40
Study: 5345935

Group type: EXPERIMENTAL
Intervention: Six-monthly chest radiographs
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no x-ray facilities)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Resected lung cancer in test series
Number of subjects: 100

Group type: COMPARATOR
Intervention: Resected lung cancer in control series
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Squamous carcinoma in test series
Number of subjects: 100

Group type: COMPARATOR
Intervention: Squamous carcinoma in control series
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adenocarcinoma in test series
Number of subjects: 100

Group type: COMPARATOR
Intervention: Adenocarcinoma in control series
Number of subjects: 100
Study: 31614308

Group type: EXPERIMENTAL
Intervention: Peer influence and peer selection
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Parental smoking
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Longitudinal data analysis
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Best friend and friends' influence
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Friends and same grade students' influence
Number of subjects: 656
Study: 31743406

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine eye drops
Number of subjects: 100

Group type: COMPARATOR
Intervention: Balanced salt solution eye drops
Number of subjects: 100
Study: 28676009

Group type: EXPERIMENTAL
Intervention: Substitute tear + probiotic mixture (Saccharomyces boulardii MUCL 53837 and Enterococcus faecium LMG S‐28935)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Substitute tear (control)
Number of subjects: 60
Study: 26212719

Group type: COMPARATOR
Intervention: Compression socks (SOCK)
Number of subjects: 20
Study: 23620478

Group type: EXPERIMENTAL
Intervention: Normoalbuminuria with DR (NA(DR+))
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Microalbuminuria without DR (MA(DR−))
Number of subjects: 1475

Group type: EXPERIMENTAL
Intervention: Microalbuminuria with DR (MA(DR+))
Number of subjects: 1475

Group type: COMPARATOR
Intervention: Normoalbuminuria without DR (NA(DR−))
Number of subjects: 1475
Study: 21368587

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg
Number of subjects: 329

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg
Number of subjects: 329
Study: 19709795

Group type: EXPERIMENTAL
Intervention: PMA (physician-manned ambulance)
Number of subjects: 977

Group type: COMPARATOR
Intervention: non-PMA (paramedic-manned ambulance)
Number of subjects: 977
Study: 17897512

Group type: EXPERIMENTAL
Intervention: Early hip spica cast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External fixator
Number of subjects: 0
Study: 15838366

Group type: EXPERIMENTAL
Intervention: Sitaxsentan (SITAX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11512646

Group type: EXPERIMENTAL
Intervention: Edrophonium 1.0 mg x kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Edrophonium 0.4 mg x kg(‐1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Edrophonium doses (0.1, 0.2, 0.4, 1 mg x kg(‐1))
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Cisatracurium 0.1 mg x kg(‐1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Edrophonium (dose not specified)
Number of subjects: 120
Study: 8826506

Group type: EXPERIMENTAL
Intervention: Topical capsaicin cream applied 3 times daily for 5 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle cream applied 3 times daily for 5 weeks
Number of subjects: 0
Study: 1728876

Group type: EXPERIMENTAL
Intervention: Oral labetalol
Number of subjects: 36

Group type: COMPARATOR
Intervention: Oral clonidine
Number of subjects: 36
Study: 3909798

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m2 I.V. day 1, observation after 500 mg/m2)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Doxorubicin (40 mg/m2 I.V. day 1; maximum 500 mg/m2) and mitolactol (135 mg/m2 orally, days 1‐10; 180 mg/m2 after maximum doxorubicin)
Number of subjects: 151
Study: 31454159

Group type: EXPERIMENTAL
Intervention: Ball abutments
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Locator abutments
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (balls and locators)
Number of subjects: 90
Study: 29503247

Group type: EXPERIMENTAL
Intervention: Microwave ablation
Number of subjects: 152

Group type: COMPARATOR
Intervention: Radiofrequency ablation
Number of subjects: 152
Study: 26921676

Group type: EXPERIMENTAL
Intervention: PZQ/ART
Number of subjects: 913

Group type: COMPARATOR
Intervention: PZQ/ART-placebo
Number of subjects: 913
Study: 24669876

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine 400 mg/day
Number of subjects: 267

Group type: COMPARATOR
Intervention: Pioglitazone 15 mg/day
Number of subjects: 267
Study: 22879929

Group type: EXPERIMENTAL
Intervention: Preemptive anidulafungin treatment based on BDG surveillance
Number of subjects: 64

Group type: COMPARATOR
Intervention: Empiric antifungal treatment based on physician preference
Number of subjects: 64
Study: 19955453

Group type: EXPERIMENTAL
Intervention: Champions leading infection prevention efforts
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Behavioral change implementation
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Quality of organizational networks
Number of subjects: 86
Study: 17181848

Group type: EXPERIMENTAL
Intervention: Stimulus position at 3 o'clock
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Stimulus position at 9 o'clock
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Stimulus position at 6 o'clock
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Stimulus position at 12 o'clock
Number of subjects: 31
Study: 15094440

Group type: EXPERIMENTAL
Intervention: 99mTc‐labelled human albumin colloid with a particle size of 0.2‐3 microm (Albu‐Res)
Number of subjects: 119

Group type: COMPARATOR
Intervention: 99mTc‐labelled albumin colloid with a particle size of < 80 nm (Nanocoll)
Number of subjects: 119
Study: 11268714

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg two to three times daily)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Gliclazide (40-80 mg twice daily)
Number of subjects: 72
Study: 9850256

Group type: EXPERIMENTAL
Intervention: Conventional eye pad and shield
Number of subjects: 83

Group type: COMPARATOR
Intervention: Clear eye shield applied without a pad
Number of subjects: 83
Study: 10525491

Group type: EXPERIMENTAL
Intervention: Chronic VVI pacing
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Reestablishment of chronic AV synchrony with DDD pacing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Chronic DDD pacing
Number of subjects: 32
Study: 2404386

Group type: EXPERIMENTAL
Intervention: Method I: Two catheter electrodes (right ventricular cathode and right atrial anode)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Method II: One catheter electrode and cutaneous patch (right ventricular cathode and cutaneous apical patch anode)
Number of subjects: 12
Study: 418655

Group type: EXPERIMENTAL
Intervention: Chest radiography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study: 31383231

Group type: EXPERIMENTAL
Intervention: NightBalance sleep position treatment (SPT) device
Number of subjects: 117

Group type: COMPARATOR
Intervention: Auto-adjusting positive airway pressure (APAP)
Number of subjects: 117
Study: 28208806

Group type: EXPERIMENTAL
Intervention: High dose OP beverage (77% OP)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Low dose OP beverage (35% OP)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (255 g)
Number of subjects: 34
Study: 25988560

Group type: EXPERIMENTAL
Intervention: pre‐S vaccine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Engerix B
Number of subjects: 82
Study: 23471586

Group type: EXPERIMENTAL
Intervention: Voluven 5 ml/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Voluven 7 ml/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Voluven 9 ml/kg
Number of subjects: 60
Study: 20674978

Group type: EXPERIMENTAL
Intervention: Number of close social network members
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Health-related support from social network members
Number of subjects: 115
Study: 20032539

Group type: EXPERIMENTAL
Intervention: AZT/lamivudine/efavirenz (n=15)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: TDF/emtricitabine/efavirenz (n=17)
Number of subjects: 32

Group type: COMPARATOR
Intervention: HIV-negative matched controls (n=15)
Number of subjects: 32
Study: 16717120

Group type: EXPERIMENTAL
Intervention: Dopamine (2.5, 5, 7.5, and 10 microg/kg per minute)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epinephrine (0.125, 0.250, 0.375, and 0.5 microg/kg per minute)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dopamine and Epinephrine (both groups)
Number of subjects: 60
Study: 15168020

Group type: EXPERIMENTAL
Intervention: 3.4 g t10c12CLA for 12 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control oil for 12 weeks
Number of subjects: 57
Study: 11331320

Group type: EXPERIMENTAL
Intervention: 5‐FU 2,600 mg/m2 by 24‐hour infusion, weekly
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: N‐phosphonoacetyl‐l‐aspartic acid 250 mg/m2 day 1, 5‐FU 2,600 mg/m2 by 24‐hour infusion day 2, weekly
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: 5‐FU 600 mg/m2 with oral leucovorin (LV) 125 mg/m2 hourly for the preceding 4 hours, weekly
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: 5‐FU 600 mg/m2 with intravenous (IV) LV 600 mg/m2, weekly
Number of subjects: 1120

Group type: EXPERIMENTAL
Intervention: 5‐FU 750 mg/m2/d IV by continuous infusion for 5 days, then 750 mg/m2 weekly, and recombinant interferon alfa‐2a 9 million units subcutaneously three times weekly
Number of subjects: 1120

Group type: COMPARATOR
Intervention: 5‐FU as a 24‐hour infusion weekly (control group)
Number of subjects: 1120
Study: 9223392

Group type: EXPERIMENTAL
Intervention: Pramlintide infusion in insulin-treated patients
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pramlintide infusion in diet/oral hypoglycaemic agents-treated patients
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study: 7964336

Group type: EXPERIMENTAL
Intervention: Clusters of childhood leukaemias
Number of subjects: 9406

Group type: COMPARATOR
Intervention: Non-clustered cases
Number of subjects: 9406
Study: 3555838

Group type: EXPERIMENTAL
Intervention: Nimodipine (40 mg three times daily)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Pizotifen (0.5 mg three times daily)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Nimodipine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Pizotifen
Number of subjects: 43
Study: 31922456

Group type: EXPERIMENTAL
Intervention: Formal research language
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Informal language about research support
Number of subjects: 303

Group type: COMPARATOR
Intervention: No information about research (Control)
Number of subjects: 303
Study: 29801444

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Promotion (MBHP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 160
Study: 28804048

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 45 minutes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Concurrent resistance and aerobic exercise for 45 minutes
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (non-exercise session at seated rest)
Number of subjects: 20
Study: 25068452

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) intervention group
Number of subjects: 240

Group type: COMPARATOR
Intervention: 1-day psycho-educational control group
Number of subjects: 240
Study: 22435369

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.1 mg/kg or 0.25 mg/kg)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Alteplase (0.9 mg/kg)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Tenecteplase (0.25 mg/kg)
Number of subjects: 75
Study: 21111307

Group type: EXPERIMENTAL
Intervention: Tecnis ZA9003 aspheric IOL
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: AF-1 VA-60BB spherical IOL
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: AcrySof SA60AT spherical IOL
Number of subjects: 65
Study: 18202419

Group type: COMPARATOR
Intervention: CISCA/VB (cyclophosphamide 400 mg/m(2) d1-2, doxorubicin 35 mg/m(2) d1-2, cisplatin 100 mg/m(2) d3/vinblastine 2.5 mg/m(2) d1-5)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: BEP (bleomycin 30 mg d1, d8, d15; etoposide 100 mg/m(2) d1-5; cisplatin 20 mg/m(2) d1-5)
Number of subjects: 190

Group type: COMPARATOR
Intervention: CISCA/VB
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: BEP
Number of subjects: 190
Study: 15904616

Group type: EXPERIMENTAL
Intervention: Laparoscopy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 122
Study: 12885718

Group type: EXPERIMENTAL
Intervention: Wine consumption
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Beer consumption
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Spirits consumption
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Beer consumption in wine drinkers
Number of subjects: 1196

Group type: EXPERIMENTAL
Intervention: Beer consumption in non-wine drinkers
Number of subjects: 1196
Study: 10566562

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study: 8739864

Group type: EXPERIMENTAL
Intervention: H1-antagonist (terfenadine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: H2-antagonist (cimetidine)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of H1 and H2 antagonists
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1816109

Group type: EXPERIMENTAL
Intervention: Oral zidovudine 250 mg twice daily combined with oral acyclovir 800 mg twice daily
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oral zidovudine 250 mg twice daily combined with lymphoblastoid interferon‐alpha 1.5 x 10(6) IU administered subcutaneously three times weekly
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 16
Study: 6312008

Group type: EXPERIMENTAL
Intervention: ACTH (20 to 30 units/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prednisone (2 mg/kg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ACTH
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ACTH and Prednisone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 24
Study: 31856714

Group type: EXPERIMENTAL
Intervention: CORIN SNPs (rs2289433, rs6823184, rs10517195, rs2271037, rs12509275)
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: SNP rs6823184 and linked SNPs (rs10049713, rs6823698, rs1866689)
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: SNP rs6823184
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: cg02955940 methylation
Number of subjects: 1462
Study: 27936374

Group type: EXPERIMENTAL
Intervention: 12-step facilitation (TSF)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Overall comparison
Number of subjects: 267
Study: 26346805

Group type: EXPERIMENTAL
Intervention: Early Surgery within 12 hours
Number of subjects: 170

Group type: COMPARATOR
Intervention: Initial Conservative Treatment
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Early Surgery
Number of subjects: 170
Study: 25852045

Group type: EXPERIMENTAL
Intervention: Drug Education in Victorian Schools program (intervention group, n=1,163)
Number of subjects: 1752

Group type: COMPARATOR
Intervention: Usual drug education program (control group, n=589)
Number of subjects: 1752
Study: 22946452

Group type: EXPERIMENTAL
Intervention: Massage group (1-hour Swedish massage)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (normal daily activities)
Number of subjects: 22
Study: 20676961

Group type: EXPERIMENTAL
Intervention: Levosimendan (n = 31)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard HF treatment (n = 29)
Number of subjects: 59
Study: 17376253

Group type: EXPERIMENTAL
Intervention: Lipuro propofol with lidocaine
Number of subjects: 328

Group type: COMPARATOR
Intervention: Lipuro propofol
Number of subjects: 328

Group type: COMPARATOR
Intervention: Diprivan with lidocaine
Number of subjects: 328

Group type: COMPARATOR
Intervention: Diprivan propofol
Number of subjects: 328
Study: 16305876

Group type: EXPERIMENTAL
Intervention: IABP‐induced pulsatile (automatic 80 bpm) CPB (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard nonpulsatile CPB with IABP discontinued during cardioplegic arrest (group A)
Number of subjects: 40
Study: 12537406

Group type: EXPERIMENTAL
Intervention: Direct stenting (DS) without predilation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional stenting with predilation (SWP)
Number of subjects: 60
Study: 9665104

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 523

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 523
Study: 7535676

Group type: EXPERIMENTAL
Intervention: Colchicine (0.6 mg twice daily)
Number of subjects: 9
Study: 2243982

Group type: EXPERIMENTAL
Intervention: Color Doppler flow imaging
Number of subjects: 30
Study: 357764

Group type: EXPERIMENTAL
Intervention: Furosemide, 40 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrochlorothiazide, 50 mg twice daily
Number of subjects: 0
Study: 30327302

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 184

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 184
Study: 28551048

Group type: EXPERIMENTAL
Intervention: Equal height staples
Number of subjects: 61

Group type: COMPARATOR
Intervention: Graduated height staples
Number of subjects: 61
Study: 26073262

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Tolterodine (2mg bid p.o.)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 36
Study: 22679249

Group type: EXPERIMENTAL
Intervention: Pitavastatin 1-4 mg
Number of subjects: 942

Group type: COMPARATOR
Intervention: Pravastatin 10-40 mg
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Pitavastatin low-dose (1 mg)
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Pitavastatin intermediate-dose (2 mg)
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Pitavastatin higher-dose (4 mg)
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Pitavastatin low doses
Number of subjects: 942

Group type: COMPARATOR
Intervention: Pravastatin low doses
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Pitavastatin intermediate doses
Number of subjects: 942

Group type: COMPARATOR
Intervention: Pravastatin intermediate doses
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Pitavastatin higher doses
Number of subjects: 942

Group type: COMPARATOR
Intervention: Pravastatin higher doses
Number of subjects: 942
Study: 22051734

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (CT) based on clinical (C) and genomic (G) risk assessment
Number of subjects: 800

Group type: COMPARATOR
Intervention: Anthracycline-based chemotherapy
Number of subjects: 800

Group type: COMPARATOR
Intervention: Docetaxel/capecitabine chemotherapy
Number of subjects: 800

Group type: COMPARATOR
Intervention: Endocrine therapy with letrozole
Number of subjects: 800

Group type: COMPARATOR
Intervention: Endocrine therapy with tamoxifen→letrozole
Number of subjects: 800
Study: 19902755

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) combined with acupoint-injection (10 sessions of EA once a day for 10 days, and 5 sessions of acupoint-injection once every two days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Single Electroacupuncture (EA) (10 sessions once a day for 10 days)
Number of subjects: 60
Study: 16600928

Group type: EXPERIMENTAL
Intervention: Protein from lean red meat
Number of subjects: 60
Study: 12570940

Group type: EXPERIMENTAL
Intervention: Intravenous glycoprotein IIb/IIIa receptor antagonists
Number of subjects: 20137

Group type: COMPARATOR
Intervention: Heparin infusion continued after the procedure
Number of subjects: 20137

Group type: COMPARATOR
Intervention: Heparin infusion discontinued after the procedure
Number of subjects: 20137
Study: 10807488

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 372

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study: 8738314

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 378

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 378

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 378
Study: 1397716

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 8
Study: 3888734

Group type: EXPERIMENTAL
Intervention: Diet and insulin
Number of subjects: 202

Group type: COMPARATOR
Intervention: Diet
Number of subjects: 202
Study: 31895283

Group type: EXPERIMENTAL
Intervention: Leg Press
Number of subjects: 19

Group type: COMPARATOR
Intervention: Free Weights
Number of subjects: 19

Group type: COMPARATOR
Intervention: Smith Machine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Squats (Free Weights and Smith Machine)
Number of subjects: 19
Study: 29692005

Group type: EXPERIMENTAL
Intervention: PF‐05280586
Number of subjects: 185
Study: 29652462

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) for decontamination of implant surface
Number of subjects: 52

Group type: COMPARATOR
Intervention: Chlorhexidine gel (CHX) followed by saline irrigation
Number of subjects: 52
Study: 24582046

Group type: EXPERIMENTAL
Intervention: Ivabradine 15 mg (single dose)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Ivabradine 10 mg (single dose)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Ivabradine 5 mg twice daily for 5 days
Number of subjects: 192